KemPharm, Inc. Forecast, price target & analysts
KemPharm, Inc. Target price 2025 - Analyst rating & recommendation
KemPharm, Inc. Classifications & Recommendation:
KemPharm, Inc. Price Target
| Target Price | $21.63 |
| Price | $6.56 |
| Potential |
229.65%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target KemPharm, Inc. 2026 .
The average KemPharm, Inc. target price is $21.63.
This is
229.65%
register free of charge
$25.00
281.10%
register free of charge
$17.00
159.15%
register free of charge
|
|
| A rating was issued by 8 analysts: 8 Analysts recommend KemPharm, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the KemPharm, Inc. stock has an average upside potential 2026 of
229.65%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 23.61 | 85.05 |
| 14.02% | 260.23% | |
| EBITDA Margin | -341.42% | -35.51% |
| 92.91% | 89.60% | |
| Net Margin | -518.29% | -24.82% |
| 103.98% | 95.21% |
8 Analysts have issued a sales forecast KemPharm, Inc. 2025 . The average KemPharm, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast KemPharm, Inc. 2025 . The average KemPharm, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 KemPharm, Inc. Analysts have issued a net profit forecast 2025. The average KemPharm, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.28 | -0.39 |
| 75.38% | 82.89% | |
| P/E | negative | |
| EV/Sales | 4.07 |
3 Analysts have issued a KemPharm, Inc. forecast for earnings per share. The average KemPharm, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Current KemPharm, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 20 2024 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 14 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 20 2024 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 14 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
